Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

Sponsor
Washington University School of Medicine
Study ID
NCT05007769
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Ramucirumab — DRUG
    Will be supplied by Lilly Oncology, free of charge to the participant
  • Atezolizumab — DRUG
    Atezolizumab will be commercially available.
  • N-803 — DRUG
    Will be supplied free of charge to the participants by ImmunityBio

Study Details

The investigators hypothesize that the addition of ramucirumab and N-803 will augment the clinical activity of atezolizumab, and in order to evaluate the exact mechanism of action of the combination, the investigators propose a comprehensive analysis of paired peripheral blood samples collected during this study.

Key Dates

Start date
Oct 31, 2021
Status verified
Oct 2021
Primary completion
Apr 30, 2024
Completion
Apr 30, 2026

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Ramucirumab + Atezolizumab + N-803
    -Ramucirumab intravenously (IV) on Day 1, atezolizumab IV on Day 1, and N-803 subcutaneous (SC) on Day 1 of each cycle. Cycles are 21 days.

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: Through completion of treatment (estimated to be 6 months) ]

Related Studies